… in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature patholological … and anatomical neuroprotection. Project Description:  Pre-clinical models will be treated with a neurotoxin called … in which alpha synuclein accumulates. Anticipated Outcome:  We expect to learn the following: Can we successfully …

… Fatigue is a common, frustrating Parkinson's disease symptom. It can feel … of Parkinson's medications . In addition to talking with your doctor, making changes to your routine, physical … Share your own advice in the comments. Access our archived webinar  on managing fatigue and pain in Parkinson's …

… Genzyme R&D Center Rich Gregory, PhD, tells MJFF how his company is developing a critical research tool for use in a clinical trial at the University of … can come together toward solving a problem.   And this is where The Michael J. Fox Foundation is playing a major role. …

… of Friday, February 9, Congress passed a spending bill to fund the government through March 23, 2018. In the … Of particular note to the Parkinson's disease (PD) community is the removal of the Medicare therapy cap, which … and speech therapy a beneficiary could receive. Previously, Congress created an exceptions process that …

… Mrs. Lily Safra has made a $1 million gift to The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support this year’s Edmond J. Safra Core Programs for PD … Safra Core Programs for PD Research were launched in 2008 to identify roadblocks along the therapeutic development …

… Objective/Rationale:  Mitochondrial dysfunction is a central modification underlying … drugs able to stabilise mitochondria (like berberine) could prevent or arrest the evolution of dopaminergic damage and … for the clinical utility of berberine in PD. Anticipated Outcome:  Overall this project is designed to allow 2 major …